Evidence map›Paper›PMID 24937094›Full record

ArticleTranslational psychiatry2014

Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy.

J C Naviaux, M A Schuchbauer, K Li, L Wang, V B Risbrough, S B Powell, R K Naviaux

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 74 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02508259 phase1 / phase2completednot on this mapstarted 2015, after this paper: background citation

The UCSD Suramin Autism Treatment-1 (SAT1) Trial

TypeinterventionalSponsorUniversity of California, San DiegoRan2015 to 2016Enrolled10ConditionsAutism Spectrum DisordersArmsSuramin, Saline
NCT06866275 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Suramin for the Treatment of Autism Trial (STAT): A Randomized, Double Blind, Crossover Trial of KZ101 in a Male Pediatric Population With Autism Spectrum Disorder

TypeinterventionalSponsorChildren's Hospital of Orange CountyRan2025 to 2028Enrolled45ConditionsAutism Spectrum Disorder (ASD)ArmsKZ101, Placebo
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Novel therapeutics in autism spectrum disorder.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  5. Article
  6. Article
  7. Possible Interaction of Suramin with Thalamic P2X Receptors and NLRP3 Inflammasome Activation Alleviates Reserpine-Induced Fibromyalgia-Like Symptoms.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Frontiers in microbiology · 2023
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

J C NaviauxDepartment of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA, USA.
M A SchuchbauerDepartment of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA, USA.
K Li1] The Mitochondrial and Metabolic Disease Center, University of California San Diego School of Medicine, San Diego, CA, USA [2] Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, USA.
L Wang1] The Mitochondrial and Metabolic Disease Center, University of California San Diego School of Medicine, San Diego, CA, USA [2] Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, USA.
V B Risbrough1] Department of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA, USA [2] Veterans Affairs Center for Excellence in Stress and Mental Health (CESAMH), La Jolla, CA, USA.
S B PowellDepartment of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA, USA.
R K Naviaux1] The Mitochondrial and Metabolic Disease Center, University of California San Diego School of Medicine, San Diego, CA, USA [2] Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, USA [3] Veterans Affairs Center for Excellence in Stress and Mental Health (CESAMH), La Jolla, CA, USA [4] Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA [5] Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA, USA.
University of California, San Diego · US

Funding

Sensitive and Treatable Periods of Brain-Redox Imbalance in SchizophreniaR01MH091407 · NIMH · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI BEHRENS, M MARGARITA, POWELL, SUSAN B · 2010 to 2014
$2.1M
NIMH NIH HHS MH091407NIMH NIH HHS R01 MH091407
6 · The paper itself

Abstract

Autism spectrum disorders (ASDs) now affect 1-2% of the children born in the United States. Hundreds of genetic, metabolic and environmental factors are known to increase the risk of ASD. Similar factors are known to influence the risk of schizophrenia and bipolar disorder; however, a unifying mechanistic explanation has remained elusive. Here we used the maternal immune activation (MIA) mouse model of neurodevelopmental and neuropsychiatric disorders to study the effects of a single dose of the antipurinergic drug suramin on the behavior and metabolism of adult animals. We found that disturbances in social behavior, novelty preference and metabolism are not permanent but are treatable with antipurinergic therapy (APT) in this model of ASD and schizophrenia. A single dose of suramin (20 mg kg(-1) intraperitoneally (i.p.)) given to 6-month-old adults restored normal social behavior, novelty preference and metabolism. Comprehensive metabolomic analysis identified purine metabolism as the key regulatory pathway. Correction of purine metabolism normalized 17 of 18 metabolic pathways that were disturbed in the MIA model. Two days after treatment, the suramin concentration in the plasma and brainstem was 7.64 μM pmol μl(-1) (±0.50) and 5.15 pmol mg(-1) (±0.49), respectively. These data show good uptake of suramin into the central nervous system at the level of the brainstem. Most of the improvements associated with APT were lost after 5 weeks of drug washout, consistent with the 1-week plasma half-life of suramin in mice. Our results show that purine metabolism is a master regulator of behavior and metabolism in the MIA model, and that single-dose APT with suramin acutely reverses these abnormalities, even in adults.

Indexed as

Social BehaviorAnimalsBehavior, AnimalBrainBrain StemChild Development Disorders, PervasiveDisease Models, AnimalMaleMetabolic Networks and PathwaysMetabolomicsMiceMice, Inbred C57BLPurinergic AntagonistsPurinesRandom AllocationSuraminPurinergic AntagonistsPurinesSuramin

Identifiers

PMID24937094
PMCPMC4080315
OpenAlexW1995530514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.